Conference
Conference
A fireside chat with biotech ecosystem key players to ignite the scaling up process of invention and bio-entrepreneurial skills
Sara is a Partner and Patent Attorney at Potter Clarkson with an academic background in microbial molecular biology. She specialises in advising and working with biotech start-ups, primarily in the industrial biotechnology and synthetic biology space. She is deeply involved in the ecosystem, sitting on a number of committees in these areas, including the Industrial Biotechnology Leadership Forum and the Bioindustry Association’s Engineering Biology Advisory Committee in the UK, and alongside Liz Fletcher at the Industrial Biotechnology Innovation Centre and Fiona Mischel at SynBioBeta, co-founded the Women in Synthetic Biology network.
Dr Emma Ball is a biotechnology commercialization expert with over 20 years’ experience. Her current role is Head of Ecosystem Development across Asia Pacific, Middle East, Africa (AMEA) at global genomics leader, Illumina (NASQAQ: ILMN). The role involves strategic partnering with startups, corporates, governments and academia to catalyze innovation in genomics across the region. Prior to joining Illumina in 2021, Emma was at biotherapeutics and vaccines company, CSL Limited (ASX: CSL) for 15 years, most recently as Global Head of Search & Evaluation and Director Strategy & BD. Prior to joining CSL, Emma worked in project management in small biotech, both ASX-listed and private. She holds a PhD from the University of Melbourne, having trained initially as a molecular biologist, and a number of business qualifications including an MBA.
Alfred works at SynBioBeta, focusing on connecting SynBio leaders in industry, academia, tech & finance. He is also Co-founder of DeSci London and a PhD candidate at Imperial College London, his research focuses on the intersection of SynBio and AI. He is passionate about moving the bioeconomy forward by enhancing communication and collaboration.
Dr. Novalia Pishesha, the co-founder and CEO of Cerberus Therapeutics, established the company in 2022. Located in Cambridge, Massachusetts, USA, Cerberus Therapeutics specializes in developing nanobody technology with a focus on autoimmunity and infectious diseases. Dr. Pishesha completed her PhD in Biological Engineering at the Massachusetts Institute of Technology (MIT) in the USA, followed by postdoctoral fellowships at both MIT and Harvard University